Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announces the appointment of their new Chief Operating Officer, Jocelyne Bath.
A new role within the executive team, this appointment speaks of the rate of growth of the business and its desire to lead with cutting edge products and processes backed up by excellent commercial management.
Jocelyne has an extensive background working in businesses from science and engineering technology sectors. Prior to joining Oxford Genetics she was Chief Revenue Officer at EYOTO, providers of cutting edge eyecare technology and before that VP-Commercial Strategy for P2i, global leaders in liquid repellent nano-coating technology.
Her early career was spent with Orange Business Services. She has comprehensive experience in product, revenue and commercial management, with early roles in product pricing and analysis leading to strategic commercial management later in her career, and more recently executive level roles.
At Oxford Genetics Jocelyne will be responsible for commercial positioning and business operations.
About joining Oxford Genetics, Jocelyne said:
Oxfordshire is a fantastic centre for science and technology, I’m delighted to be part of the Oxford Genetics team and looking forward to the journey ahead. I’ve joined at an exciting time, with innovative solutions, a strong team and sound backing, Oxford Genetics has a bright future.”
Oxford Genetics has gone from strength to strength over the past 18 months, signing supply and license agreements with key customers, opening offices in the US and strategically adding new and innovative solutions to its portfolio.